Comparative outcomes of abiraterone and androgen receptor inhibitors (ARPIs) in metastatic castration-sensitive prostate cancer (mCSPC): A real-world analysis from the TriNetX database.
Authors: Haris Sohail, Jennifer Collins, Kok Hoe Chan
Published: 2025-05-28
DOI:
10.1200/jco.2025.43.16_suppl.e17119
Source:
Full article
Abstract
e17119